Results 161 to 170 of about 149,498 (247)

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents. [PDF]

Pharmaceuticals (Basel)
Kagaya M, Uesawa Y.
europepmc   +1 more source

Supramolecular Assembly of Stepped‐Persistent ROS Nanogenerator for Sustained Tumor Immunotherapy

Advanced Science, EarlyView.
ROS catalytic systems often fail to achieve both effective tumor elimination and persistent immune activation due to their monotonous ROS production profiles. A stepped‐persistent ROS nanogenerator was developed by supramolecularly assembling multiple ROS generation modules within a nanofiber structure to simultaneously extend ROS generation duration ...
Zhenqiang Wang, Ming Qin, Wenjing Lai, Shiwen Chen, Fengling Wang, Dandan Xie, Maohua Chen, Changpeng Hu, Kui Wang, Rong Zhang, Guobing Li   +10 more
wiley   +1 more source

Design, Synthesis, and Evaluation of Cytotoxic Effects of Functional Fatty Acid Derivatives as Potential Antineoplastic Agents for Breast Cancer. [PDF]

Iran J Pharm Res
Hosseini M, Kobarfard F, Amidi S, Mokhtari S, Sedaghat A, Shahhosseini S.   +5 more
europepmc   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source

pH-responsive niosome-based nanocarriers of antineoplastic agents. [PDF]

RSC Adv
Gugleva V, Mihaylova R, Momekov G, Kamenova K, Forys A, Trzebicka B, Petrova M, Ugrinova I, Momekova D, Petrov PD.   +9 more
europepmc   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Design and Synthesis of Organic Molecules as Antineoplastic Agents. [PDF]

Molecules, 2020
Boga C, Micheletti G.
europepmc   +1 more source

PGK1 Suppresses CD8+ T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
PGK1 in tumor cells upregulates CCL2 expression through activation of the AKT/GSK‐3β/β‐catenin signaling axis, thereby promoting the recruitment and M2 polarization of TAMs and ultimately impairing the infiltration and activation of CD8+ T cells within the HCC tumor microenvironment. ABSTRACT Patients with advanced hepatocellular carcinoma (HCC) have a
Xi Liu, Jianpeng Liu, Zhihao Zhang, Xizhi Yu, Junjie Qian, Limin Ding, Qinchuan Wu, Zhe Yang, Xing‐Yu Luo, Xinjiang Ding, Rong Su, Xiaobo Yu, Yiting Qiao, Shengyong Yin, Haiyang Xie, Lin Zhou, Yuanxing Liu, Shusen Zheng   +17 more
wiley   +1 more source

Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic. [PDF]

PLoS One
McNabb L, Metrot E, Ferrington M, Sunderland B, Parsons R, Copeland TS, Corscadden S, Tong S, Czarniak P.   +8 more
europepmc   +1 more source